Cellectar Biosciences Inc. has received a peer-reviewed National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant of approximately $2 million from the National Cancer Institute (NCI), according to a statement from the company. The funding will support a rare lymphoma study initiated in January 2021 by the company. The study is expected to take approximately 18 months to fully enroll. Cellectar is based in New Jersey, with a location at 8383 Greenway Blvd., #600, in Middleton.
Get Our Email Newsletter
The companies, people and issues shaping business in Madison and the Capital Region.
